Nemesis Bioscience today announced the expansion of its presence in Aberystwyth by opening a new pre-clinical development facility at the University. Having become members at the Aberystwyth Innovation and Enterprise Campus in August 2018, the company grew its operations during the following months by recruiting new full-time staff and moving into laboratory space at the
New Chairman Brings “Wealth of Experience” to Pioneering Biotech Firm Simon Sturge, Executive Vice President of Business, Operations and Strategy at Merck Healthcare, is today confirmed as
PHOTO: From Left: Prof Conrad Lichtenstein (Nemesis CSO), Dr Frank Massam (Nemesis CEO), Dr Takeshi Shiota (Shionogi SVP, Pharmaceutical Research Division) and Dr Kai Stoeber
Nemesis Bioscience today announced the appointment of Dr Mark McCamish as Scientific Advisor for the development of its suite of Bacterial Cybergenetics© technologies. These include
Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed funds raised to more than £700,000, and the commencement of
Nemesis Bioscience today announced the appointment of Dr Alastair Riddell as non-executive Chairman. The appointment is effective from the 1st July and will bring Alastair’s
Nemesis Bioscience has beaten tough competition from across the country to win a place to showcase its product at the UK’s largest innovation show in
Nemesis Bioscience Ltd (Cambridge, UK) announced today that it has received a funding award from the UK’s innovation agency, Innovate UK. The Smart Award will
Nemesis Bioscience Ltd has raised £300,000 in seed funding from Angel investors and from Finance Wales to extend the application of its proprietary biological therapeutics
Nemesis Bioscience Ltd (Cambridge, UK) announced today that it has been awarded an Entrepreneurship Award by King’s College, Cambridge. The King’s College judges, who include current members of the College as well as alumni Gerard Mizrahi, Hermann Hauser and Stuart Lyons, reached their decision after detailed presentations on the company’s business plan, technology and intellectual